ArticleScientific reports2023
Developing a new multi-featured chitosan-quinoline Schiff base with potent antibacterial, antioxidant, and antidiabetic activities: design and molecular modeling simulation.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- Development of novel salicylic acid derivatives with dual anti-inflammatory and anti-arthritic potentials: synthesis,RSC advances · 2026Article
- Pharmacological and Biological Efficacy of Chitosan-Based Materials.International journal of molecular sciences · 2025Review
- Enhancement of biological properties in casein protein through functionalization with cinnamaldehydeRSC advances · 2025Article
- High-Performance Polyimide Membranes Containing Graphene Oxide for Reverse Osmosis Desalination.ACS omega · 2025Article
- Exploring novel of 1,2,4-triazolo[4,3-a]quinoxaline sulfonamide regioisomers as anti-diabetic and anti-Alzheimer agents with in-silico molecular docking simulation.Scientific reports · 2025Article
- Synthesis and structural insights of bis(2-methoxy-6-{[(2-methylpropyl)imino]methyl}phenolato) nickel (II) complex through DFT and docking investigations.Scientific reports · 2025Article
- Chitosan-Based Schiff Bases (CSBs) and Their Metal Complexes: Promising Antimicrobial Agents.Molecules (Basel, Switzerland) · 2025Review
- Chitosan-Based Nanoparticles Targeted Delivery System: In Treatment Approach for Dyslipidemia.International journal of nanomedicine · 2025Review
- Exploring the Potential Biological Activities of Pyrazole-Based Schiff Bases as Anti-Diabetic, Anti-Alzheimer's, Anti-Inflammatory, and Cytotoxic Agents:Pharmaceuticals (Basel, Switzerland) · 2024Article
- Innovation of 6-sulfonamide-2RSC advances · 2024Article
- Prospects of sustainable polymers.Scientific reports · 2024Article
- Quinoline as a Privileged Structure: A Recent Update on Synthesis and Biological Activities.Current topics in medicinal chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new chitosan Schiff base was developed via the reaction of chitosan (CH) with 2-chloro-3-formyl-7-ethoxy quinoline (Q) derivative. The alteration in the chemical structure and morphology of CHQ derivative was confirmed by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.